お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ

株式会社グローバルインフォメーション
市場調査レポート
商品コード
487422

オーソバイオロジクスの世界市場予測

Global Orthobiologics Market Forecast 2019-2027

出版日: | 発行: Inkwood Research | ページ情報: 英文 127 Pages | 納期: 2-3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=104.53円
オーソバイオロジクスの世界市場予測
出版日: 2019年03月20日
発行: Inkwood Research
ページ情報: 英文 127 Pages
納期: 2-3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

当レポートでは、オーソバイオロジクスの世界市場について分析し、市場の基本構造や、市場成長への主な影響要因、市場動向と今後の見通し、製品・用途・地域別の詳細な動向、市場発展の方向性、競合情勢、主要企業のプロファイルなどをまとめています。

第1章 調査範囲

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場概要

  • 成長促進要因
  • 成長阻害要因
  • 市場の機会
  • 市場の課題

第5章 市場区分

  • 製品別
    • 脱灰骨基質(DBM)
    • 同種移植片
    • 骨形成タンパク質(BMP)
    • 関節内補充薬
    • 合成代替移植骨
    • 幹細胞療
  • 用途別
    • 脊椎固定
    • 外傷修復
    • 再建術

第6章 重要分析

  • ファイブフォース分析
  • PESTEL分析
  • 市場機会の指標
  • バリューチェーン分析
  • ベンダー概要

第7章 地域分析

  • 北米
    • 米国
    • カナダ
  • 欧州
    • 英国
    • フランス
    • ドイツ
    • スペイン
    • イタリア
    • その他
  • アジア太平洋
    • インド
    • 中国
    • 日本
    • オーストラリア
    • その他
  • その他の地域
    • ラテンアメリカ
    • 中東・北アフリカ
    • アフリカ

第8章 競合情勢

  • 市場シェア分析
  • 合併・買収

第9章 企業プロファイル

図表

LIST OF TABLES

  • TABLE 1 GLOBAL ORTHOBIOLOGICS MARKET BY REGION 2019-2027 ($ MILLION)
  • TABLE 2 OLDER POPULATION BY AGE GROUP ( 1900 TO 2050)
  • TABLE 3 POST-SURGERY COMPLICATIONS
  • TABLE 4 GLOBAL ORTHOBIOLOGICS MARKET BY END USER 2019-2027 ($ MILLION)
  • TABLE 5 GLOBAL HOSPITALS MARKET BY REGION 2019-2027 ($ MILLION)
  • TABLE 6 GLOBAL ORTHOPEDIC CLINICS MARKET BY REGION 2019-2027 ($ MILLION)
  • TABLE 7 GLOBAL ORTHOBIOLOGICS MARKET BY PRODUCTS 2019-2027 ($ MILLION)
  • TABLE 8 GLOBAL DEMINERALIZED BONE MATRIX (DBM) MARKET BY REGION 2019-2027 ($ MILLION)
  • TABLE 9 GLOBAL ALLOGRAFT MARKET BY REGION 2019-2027 ($ MILLION)
  • TABLE 10 GLOBAL BONE MORPHOGENETIC PROTEIN (BMP) MARKET BY REGION 2019-2027 ($ MILLION)
  • TABLE 11 GLOBAL VISCOSUPPLEMENTATION MARKET BY REGION 2019-2027 ($ MILLION)
  • TABLE 12 SINGLE INJECTION IN VISCOSUPPLEMENTATION COST AND DIFFERENT BRAND
  • TABLE 13 MULTIPLE INJECTIONS IN VISCOSUPPLEMENTATION
  • TABLE 14 GLOBAL SYNTHETIC BONE SUBSTITUTES MARKET BY REGION 2019-2027 ($ MILLION)
  • TABLE 15 GLOBAL STEM CELL THERAPY MARKET BY REGION 2019-2027 ($ MILLION)
  • TABLE 16 GLOBAL OTHER PRODUCTS MARKET BY REGION 2019-2027 ($ MILLION)
  • TABLE 17 GLOBAL ORTHOBIOLOGICS MARKET BY APPLICATION 2019-2027 ($ MILLION)
  • TABLE 18 GLOBAL SPINAL FUSION MARKET BY REGION 2019-2027 ($ MILLION)
  • TABLE 19 GLOBAL TRAUMA REPAIR MARKET BY REGION 2019-2027 ($ MILLION)
  • TABLE 20 GLOBAL RECONSTRUCTIVE SURGERY MARKET BY REGION 2019-2027 ($ MILLION)
  • TABLE 21 GLOBAL TENDON AND LIGAMENT MARKET BY REGION 2019-2027 ($ MILLION)
  • TABLE 22 GLOBAL OTHER APPLICATIONS MARKET BY REGION 2019-2027 ($ MILLION)
  • TABLE 23 GLOBAL ORTHOBIOLOGICS MARKET BY REGION 2019-2027 ($ MILLION)
  • TABLE 24 NORTH AMERICA ORTHOBIOLOGICS MARKET BY COUNTRY 2019-2027 ($ MILLION)
  • TABLE 25 EUROPE ORTHOBIOLOGICS MARKET BY COUNTRY 2019-2027 ($ MILLION)
  • TABLE 26 AGE STRUCTURE OF GERMANY 2017
  • TABLE 27 ASIA-PACIFIC ORTHOBIOLOGICS MARKET BY COUNTRY 2019-2027 ($ MILLION)
  • TABLE 28 SPORTS INJURIES CAUSED IN AUSTRALIA BY SPORTS IN 2016
  • TABLE 29 REST OF THE WORLD ORTHOBIOLOGICS MARKET 2019-2027 (IN $ MILLION)

LIST OF FIGURES

  • FIGURE 1 GLOBAL ORTHOBIOLOGICS MARKET 2019-2027 ($ MILLION)
  • FIGURE 2 INCREASING DEMAND OF MINIMAL INVASIVE TECHNOLOGIES 2010-2025 ($ MILLION)
  • FIGURE 3 GLOBAL ORTHOBIOLOGICS MARKET SHARE BY END USER 2018 & 2027 (%)
  • FIGURE 4 GLOBAL ORTHOBIOLOGICS MARKET BY HOSPITALS 2019-2027 ($ MILLION)
  • FIGURE 5 GLOBAL ORTHOBIOLOGICS MARKET BY ORTHOPEDIC CLINICS 2019-2027 ($ MILLION)
  • FIGURE 6 GLOBAL ORTHOBIOLOGICS MARKET SHARE BY PRODUCTS 2018 & 2027 (%)
  • FIGURE 7 GLOBAL ORTHOBIOLOGICS MARKET BY DEMINERALIZED BONE MATRIX (DBM) 2019-2027 ($ MILLION)
  • FIGURE 8 GLOBAL ORTHOBIOLOGICS MARKET BY ALLOGRAFT 2019-2027 ($ MILLION)
  • FIGURE 9 GLOBAL ORTHOBIOLOGICS MARKET BY BONE MORPHOGENETIC PROTEIN (BMP) 2019-2027 ($ MILLION)
  • FIGURE 10 GLOBAL ORTHOBIOLOGICS MARKET BY VISCOSUPPLEMENTATION 2019-2027 ($ MILLION)
  • FIGURE 11 GLOBAL VISCOSUPPLEMENTATION MARKET BY ONE-INJECTION 2019-2027 ($ MILLION)
  • FIGURE 12 GLOBAL VISCOSUPPLEMENTATION MARKET BY THREE-INJECTION 2019-2027 ($ MILLION)
  • FIGURE 13 GLOBAL VISCOSUPPLEMENTATION MARKET BY FIVE-INJECTION 2019-2027 ($ MILLION)
  • FIGURE 14 GLOBAL ORTHOBIOLOGICS MARKET BY SYNTHETIC BONE SUBSTITUTES 2019-2027 ($ MILLION)
  • FIGURE 15 GLOBAL ORTHOBIOLOGICS MARKET BY STEM CELL THERAPY 2019-2027 ($ MILLION)
  • FIGURE 16 GLOBAL ORTHOBIOLOGICS MARKET BY OTHER PRODUCTS 2019-2027 ($ MILLION)
  • FIGURE 17 GLOBAL ORTHOBIOLOGICS MARKET SHARE BY APPLICATION 2018 & 2027 (%)
  • FIGURE 18 GLOBAL ORTHOBIOLOGICS MARKET BY SPINAL FUSION 2019-2027 ($ MILLION)
  • FIGURE 19 GLOBAL ORTHOBIOLOGICS MARKET BY TRAUMA REPAIR 2019-2027 ($ MILLION)
  • FIGURE 20 GLOBAL ORTHOBIOLOGICS MARKET BY RECONSTRUCTIVE SURGERY 2019-2027 ($ MILLION)
  • FIGURE 21 GLOBAL ORTHOBIOLOGICS MARKET BY TENDON AND LIGAMENT 2019-2027 ($ MILLION)
  • FIGURE 22 GLOBAL ORTHOBIOLOGICS MARKET BY OTHER APPLICATIONS 2019-2027 ($ MILLION)
  • FIGURE 23 PORTER'S FIVE FORCE MODEL
  • FIGURE 24 GLOBAL ORTHOBIOLOGICS MARKET REGIONAL OUTLOOK 2018 & 2027 (%)
  • FIGURE 25 HEALTHCARE EXPENDITURE IN THE UNITED STATES 2014 & 2025 (% OF GDP)
  • FIGURE 26 THE UNITED STATES ORTHOBIOLOGICS MARKET 2019-2027 ($ MILLION)
  • FIGURE 27 CANADA ORTHOBIOLOGICS MARKET 2019-2027 ($ MILLION)
  • FIGURE 28 EUROPE ORTHOBIOLOGICS MARKET BY COUNTRY 2018 & 2027
  • FIGURE 29 THE UNITED KINGDOM ORTHOBIOLOGICS MARKET 2019-2027 ($ MILLION)
  • FIGURE 30 FRANCE ORTHOBIOLOGICS MARKET 2019-2027 ($ MILLION)
  • FIGURE 31 GERMANY ORTHOBIOLOGICS MARKET 2019-2027 ($ MILLION)
  • FIGURE 32 SPAIN ORTHOBIOLOGICS MARKET, 2019-2027 ($ MILLION)
  • FIGURE 33 ITALY ORTHOBIOLOGICS MARKET, 2019-2027 ($ MILLION)
  • FIGURE 34 REST OF EUROPE ORTHOBIOLOGICS MARKET 2019-2027 ($ MILLION)
  • FIGURE 35 ASIA PACIFIC ORTHOBIOLOGICS MARKET BY COUNTRY 2018 & 2027
  • FIGURE 36 GROWING AGING POPULATION RATE 2010 AND 2050
  • FIGURE 37 INDIA ORTHOBIOLOGICS MARKET 2019-2027 ($ MILLION)
  • FIGURE 38 CHINA ORTHOBIOLOGICS MARKET 2019-2027 ($ MILLION)
  • FIGURE 39 JAPAN ORTHOBIOLOGICS MARKET 2019-2027 ($ MILLION)
  • FIGURE 40 AUSTRALIA ORTHOBIOLOGICS MARKET 2019-2027 ($ MILLION)
  • FIGURE 41 SOUTH KOREA ORTHOBIOLOGICS MARKET 2019-2027 ($ MILLION)
  • FIGURE 42 REST OF ASIA-PACIFIC ORTHOBIOLOGICS MARKET 2019-2027 ($ MILLION)
  • FIGURE 43 LATIN AMERICA ORTHOBIOLOGICS MARKET 2019-2027 (IN $ MILLION)
  • FIGURE 44 MIDDLE EAST AND AFRICA ORTHOBIOLOGICS MARKET 2019-2027 (IN $ MILLION)
  • FIGURE 45 ORTHOBIOLOGICS COMPANY MARKET SHARE 2018 (% )
目次
Product Code: 4656

KEY FINDINGS

Orthobiologics are substances that orthopedic surgeons use to help injuries heal more quickly. They are used to improve the healing of broken bones and injured muscles, tendons, and ligaments. These products are made from substances that are naturally available in the human body. When they are used in higher concentrations, orthobiologics substances help speed up the healing process.

The demand for rapid recovery coupled with reduced hospital stay is one of the main factors promoting the growth of this market. The global orthobiologics market is growing at a CAGR of 5.14% in the forecasting period 2019-2027.

MARKET INSIGHTS

The increasing rise in the geriatric population is giving rise to implantable medical devices thereby giving rise to conditions like arthritis thus boosting the growth of the market. According to the WHO, there has been a substantial rise in the global geriatric population; the group of people above 65 years of age is the fastest growing population segment. This segment is expected to grow from 13% in 2010 to 53% by 2022.

Although, the healthcare reorganizations are assessed to have affected the orthobiologics surgeons. Such organizations, restrict a doctor from owing future constructed hospitals. The law stops existing doctors owned facilities from further adding investors and thereby limiting the growth of the market.

Increasing disposable income globally is estimated to be one of the factors that are creating numerous expansion opportunities for the growth of the orthobiologics market and further leaving a positive impact.

REGIONAL INSIGHTS

The global orthobiologics market has been geographically segmented by four major regions, which are North America, Europe, Asia-Pacific and the Rest of World. The North America region is the dominating market in recent years due to increased awareness regarding biological implants and thereby leaving a positive impact on the market.

Also, in the US in 2016, around 53 million people are suffering from arthritis, and about 78 million people are suffering from low back and neck pain. The rising incidence of sports injuries coupled with an increase in diseases are further boosting the market demand.

COMPETITIVE ANALYSIS

AAP Implantate AG, Allosource, Amedica Corporation, Baxter International Inc., Conmed Corporation, Depuy Inc. (Acquired By Johnson And Johnson), Exactech Inc., Integra Lifesciences Holding Corporation, Medtronic Inc., Nuvasive Inc., RTI Surgical Sanofi, Smith & Nephew Plc, Stryker Corporation and Zimmer Biomet Inc. are the major companies mentioned in the report.

Table of Contents

1. RESEARCH SCOPE

  • 1.1. STUDY GOALS
  • 1.2. SCOPE OF THE MARKET STUDY
  • 1.3. WHO WILL FIND THIS REPORT USEFUL?
  • 1.4. STUDY AND FORECASTING YEARS

2. RESEARCH METHODOLOGY

  • 2.1. SOURCES OF DATA
    • 2.1.1. SECONDARY DATA
    • 2.1.2. PRIMARY DATA
  • 2.2. TOP-DOWN APPROACH
  • 2.3. BOTTOM-UP APPROACH
  • 2.4. DATA TRIANGULATION

3. EXECUTIVE SUMMARY

  • 3.1. MARKET SUMMARY
  • 3.2. KEY FINDINGS
    • 3.2.1. HOSPITALS ARE THE LARGEST REVENUE GENERATING END-USER
    • 3.2.2. SPINAL FUSION IS THE FASTEST GROWING APPLICATION
    • 3.2.3. VISCOSUPPLEMENTATION HOLDS THE LARGEST MARKET SHARE IN TERMS OF PRODUCTS

4. MARKET DYNAMICS

  • 4.1. MARKET SCOPE & DEFINITION
  • 4.2. MARKET DRIVERS
    • 4.2.1. SURGING DEMAND FOR SPINAL FUSION SURGERIES
    • 4.2.2. INCREASING GERIATRIC POPULATION
    • 4.2.3. INCREASE ORTHOPAEDIC RELATED DISEASES DUE TO LIFESTYLE CHOICES
    • 4.2.4. TECHNOLOGICAL ADVANCEMENT
  • 4.3. MARKET RESTRAINTS
    • 4.3.1. STRINGENT GOVERNMENT POLICIES
    • 4.3.2. POST-SURGERY COMPLICATIONS
    • 4.3.3. HIGH COST OF ORTHOPEDICS IMPLANTS
  • 4.4. MARKET OPPORTUNITIES
    • 4.4.1. INCREASED UTILIZATION OF BONE REGENERATION TECHNOLOGY
    • 4.4.2. GROWING DISPOSABLE INCOME
    • 4.4.3. EXPANSION OF COST EFFECTIVE MEDICAL PRODUCTS
    • 4.4.4. HUGE MARKET OPPORTUNITIES IN DEVELOPING COUNTRIES
  • 4.5. MARKET CHALLENGES
    • 4.5.1. HIGH COST OF SPINAL FUSION SURGERY
    • 4.5.2. POOR PERFORMANCE OF BONE GRAFT SUBSTITUTE

5. MARKET BY END-USER

  • 5.1. HOSPITALS
  • 5.2. ORTHOPEDIC CLINICS

6. MARKET BY PRODUCTS

  • 6.1. DEMINERALIZED BONE MATRIX (DBM)
  • 6.2. ALLOGRAFT
  • 6.3. BONE MORPHOGENETIC PROTEIN (BMP)
  • 6.4. VISCOSUPPLEMENTATION
    • 6.4.1. ONE-INJECTION
    • 6.4.2. THREE-INJECTION
    • 6.4.3. FIVE-INJECTION
  • 6.5. SYNTHETIC BONE SUBSTITUTES
  • 6.6. STEM CELL THERAPY
  • 6.7. OTHER PRODUCTS

7. MARKET BY APPLICATION

  • 7.1. SPINAL FUSION
  • 7.2. TRAUMA REPAIR
  • 7.3. RECONSTRUCTIVE SURGERY
  • 7.4. TENDON AND LIGAMENT
  • 7.5. OTHER APPLICATIONS

8. KEY ANALYTICS

  • 8.1. PORTER'S FIVE FORCE MODEL
    • 8.1.1. THREAT OF NEW ENTRANTS
    • 8.1.2. THREAT OF SUBSTITUTE
    • 8.1.3. BARGAINING POWER OF BUYER
    • 8.1.4. BARGAINING POWER OF SUPPLIER
    • 8.1.5. INTENSITY OF COMPETITIVE RIVALRY
  • 8.2. PESTEL ANALYSIS
  • 8.3. PATENT ANALYSIS
  • 8.4. KEY BUYING CRITERIA
  • 8.5. VALUE CHAIN ANALYSIS
  • 8.6. OPPORTUNITY MATRIX

9. GEOGRAPHICAL ANALYSIS

  • 9.1. NORTH AMERICA
    • 9.1.1. THE UNITED STATES
    • 9.1.2. CANADA
  • 9.2. EUROPE
    • 9.2.1. THE UNITED KINGDOM
    • 9.2.2. FRANCE
    • 9.2.3. GERMANY
    • 9.2.4. SPAIN
    • 9.2.5. ITALY
    • 9.2.6. REST OF EUROPE
  • 9.3. ASIA-PACIFIC
    • 9.3.1. INDIA
    • 9.3.2. CHINA
    • 9.3.3. JAPAN
    • 9.3.4. AUSTRALIA
    • 9.3.5. SOUTH KOREA
    • 9.3.6. REST OF ASIA-PACIFIC
  • 9.4. REST OF WORLD
    • 9.4.1. LATIN AMERICA
    • 9.4.2. MIDDLE EAST AND AFRICA

10. COMPETITIVE LANDSCAPE

  • 10.1. MARKET SHARE ANALYSIS
  • 10.2. COMPANY PROFILES
    • 10.2.1. AAP IMPLANTATE AG
      • 10.2.1.1. COMPANY OVERVIEW
      • 10.2.1.2. PRODUCT PORTFOLIO
      • 10.2.1.3. SCOT ANALYSIS
    • 10.2.2. ALLOSOURCE
      • 10.2.2.1. COMPANY OVERVIEW
      • 10.2.2.2. PRODUCT PORTFOLIO
      • 10.2.2.3. SCOT ANALYSIS
      • 10.2.2.4. STRATEGIC INITIATIVE
    • 10.2.3. AMEDICA CORPORATION
      • 10.2.3.1. COMPANY OVERVIEW
      • 10.2.3.2. PRODUCT PORTFOLIO
      • 10.2.3.3. SCOT ANALYSIS
      • 10.2.3.4. STRATEGIC INITIATIVES
    • 10.2.4. BAXTER INTERNATIONAL INC.
      • 10.2.4.1. MARKET OVERVIEW
      • 10.2.4.2. PRODUCT PORTFOLIO
      • 10.2.4.3. SCOT ANALYSIS
      • 10.2.4.4. STRATEGIC INITIATIVES
    • 10.2.5. CONMED CORPORATION
      • 10.2.5.1. COMPANY OVERVIEW
      • 10.2.5.2. PRODUCT PORTFOLIO
    • 10.2.6. DEPUY INC. (ACQUIRED BY JOHNSON AND JOHNSON)
      • 10.2.6.1. COMPANY OVERVIEW
      • 10.2.6.2. PRODUCT PORTFOLIO
      • 10.2.6.3. SCOT ANALYSIS
      • 10.2.6.4. STRATEGIC INITIATIVES
    • 10.2.7. EXACTECH INC.
      • 10.2.7.1. COMPANY OVERVIEW
      • 10.2.7.2. PRODUCT PORTFOLIO
      • 10.2.7.3. STRATEGIC INITIATIVES
    • 10.2.8. INTEGRA LIFESCIENCES HOLDING CORPORATION
      • 10.2.8.1. COMPANY OVERVIEW
      • 10.2.8.2. PRODUCT PORTFOLIO
      • 10.2.8.3. SCOT ANALYSIS
      • 10.2.8.4. STRATEGIC INITIATIVES
    • 10.2.9. MEDTRONIC INC.
      • 10.2.9.1. COMPANY OVERVIEW
      • 10.2.9.2. PRODUCT PORTFOLIO
      • 10.2.9.3. STRATEGIC INITIATIVES
    • 10.2.10. NUVASIVE INC.
      • 10.2.10.1. COMPANY OVERVIEW
      • 10.2.10.2. PRODUCT PORTFOLIO
      • 10.2.10.3. SCOT ANALYSIS
      • 10.2.10.4. STRATEGIC INITIATIVES
    • 10.2.11. RTI SURGICAL
      • 10.2.11.1. COMPANY OVERVIEW
      • 10.2.11.2. PRODUCT PORTFOLIO
      • 10.2.11.3. SCOT ANALYSIS
      • 10.2.11.4. STRATEGIC INITIATIVES
    • 10.2.12. SANOFI
      • 10.2.12.1. COMPANY OVERVIEW
      • 10.2.12.2. PRODUCT PORTFOLIO
      • 10.2.12.3. SCOT ANALYSIS
      • 10.2.12.4. STRATEGIC INITIATIVES
    • 10.2.13. SMITH & NEPHEW PLC
      • 10.2.13.1. COMPANY OVERVIEW
      • 10.2.13.2. PRODUCT PORTFOLIO
      • 10.2.13.3. STRATEGIC INITIATIVES
    • 10.2.14. STRYKER CORPORATION
      • 10.2.14.1. COMPANY OVERVIEW
      • 10.2.14.2. PRODUCT PORTFOLIO
      • 10.2.14.3. STRATEGIC INITIATIVES
    • 10.2.15. ZIMMER BIOMET INC.
      • 10.2.15.1. COMPANY OVERVIEW
      • 10.2.15.2. PRODUCT PORTFOLIO
      • 10.2.15.3. SCOT ANALYSIS
      • 10.2.15.4. STRATEGIC INITIATIVES
株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.